Risedronate

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 2253 publications

A novel approach for discriminating lipophilic bisphosphonate-based pharmaceuticals using a potentiometric array.

A novel approach for discriminating lipophilic bisphosphonate-based pharmaceuticals using a potentiometric array.

Journal: Analytical methods : advancing methods and applications

Published: February 09, 2026

Expected change: a new concept for monitoring patients on oral bisphosphonates.

Expected change: a new concept for monitoring patients on oral bisphosphonates.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: February 08, 2026

Adequacy of pharmacological prescriptions in women with postmenopausal osteoporosis attended in a Primary Care center

Adequacy of pharmacological prescriptions in women with postmenopausal osteoporosis attended in a Primary Care center

Journal: Atencion primaria

Published: November 04, 2025

Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam study.

Bisphosphonates use is associated with increased coronary artery calcification in the general population: The Rotterdam study.

Journal: Atherosclerosis plus

Published: October 14, 2025

DoE-based Development of Transdermal Risedronate-laden Cubosomes: In Vitro Characterization, Drug Deposition, and In Vivo Permeation in Rats.

DoE-based Development of Transdermal Risedronate-laden Cubosomes: In Vitro Characterization, Drug Deposition, and In Vivo Permeation in Rats.

Journal: AAPS PharmSciTech

Published: October 08, 2025

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.

Cost-Effectiveness of Biosimilar Denosumab Versus Bisphosphonates in Postmenopausal Osteoporosis.

Journal: PharmacoEconomics - open

Published: October 02, 2025

Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling.

Risedronate attenuates renal fibrosis by targeting prenylation-dependent RhoA/ROCK1 and ERK/NF-κB signaling.

Journal: Naunyn-Schmiedeberg's archives of pharmacology

Published: September 20, 2025

Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases.

Severe cutaneous adverse reactions to anti-osteoporosis drugs: a real-world pharmacovigilance study using the FDA Adverse Event Reporting System database and a review of published cases.

Journal: Frontiers in pharmacology

Published: September 18, 2025

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion.

Association of Osteoporosis and Bone-Strengthening Medications with Postoperative Outcomes Following Transforaminal Lumbar Interbody Fusion.

Journal: World neurosurgery

Published: September 15, 2025

Enhancement of oral bioavailability of risedronate through xyloglucan rafts.

Enhancement of oral bioavailability of risedronate through xyloglucan rafts.

Journal: Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques

Published: September 02, 2025

Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs.

Targeting SARS-CoV-2 Mpro and PLpro by Repurposing Clinically Approved Drugs.

Journal: Viruses

Published: August 29, 2025

Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021.

Prescription Trends by Orthopedic Surgery Provider: Review of the Medicare Part D Prescribers - by Provider and Drug, 2013-2021.

Journal: Orthopedics

Published: August 11, 2025

Showing 1-12 of 2,253

Last Updated: 04/28/2026